Company news
Helix Biopharma Corp. (TSX:HBP) news
Helix Biopharma Corp. news releases on 6ix. Latest, Dec 17, 2007: Helix BioPharma announces $16.9 million private placement of common shares
Press releases — page 4
Helix BioPharma announces $16.9 million private placement of common shares
December 17, 2007
Helix BioPharma Corp. announces management changes
November 15, 2007
Helix BioPharma Corp. announces fiscal 2007 results
October 26, 2007
Helix BioPharma Chairman resigns
October 15, 2007
Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
October 11, 2007
Helix BioPharma awarded U.S. Patent for DOS47 adjunct chemotherapy applications
September 17, 2007
Helix BioPharma announces Q3 2007 financial results
June 13, 2007
Helix BioPharma awarded first U.S. Patent for DOS47
May 3, 2007
Helix BioPharma Corp. announces positive phase II clinical results with its Topical Interferon Alpha-2b
April 2, 2007
Helix BioPharma Announces Q2 2007 Financial Results
March 8, 2007
Helix Biopharma to Present L-DOS47 Lung Cancer Research Findings at the Fourth International Conference on Tumor Microenvironment in Florence, Italy
March 5, 2007
Helix BioPharma to Present L-DOS47 Lung Cancer Research Findings at Keystone Symposia Meeting in Lake Louise, Alberta
February 1, 2007
2007 - A Pivotal Year for Helix
January 18, 2007
International Penta has not fully disclosed the nature of its Helix share position
January 16, 2007
Helix BioPharma Corp. responds to Penta's January 13, 2007 press release
January 15, 2007
Helix BioPharma Corp. responds to Penta's January 11, 2007 press release
January 12, 2007
Helix Biopharma Corp. responds to Penta's January 11, 2007 press release
January 12, 2007
ISS Recommends Helix Shareholders Vote "FOR" Management's Slate of Directors and Private Placement
January 11, 2007
Helix BioPharma Corp. responds to dissident proxy circular
January 10, 2007
Helix Biopharma Corp. responds to dissident proxy circular
January 10, 2007
Helix BioPharma Corp. signs L-DOS47 manufacturing agreement with BioVectra dcl
January 5, 2007
Helix BioPharma Corp. responds to Penta
December 22, 2006
Helix Biopharma announces Q1 2007 financial results
December 13, 2006
Helix BioPharma Corp. initiates enrollment in Phase II clinical trial with Topical Interferon Alpha-2b in patients with ano-genital warts
December 11, 2006
Helix BioPharma Corp. announces change of date and type of meeting for Annual General Meeting
December 8, 2006
Helix Biopharma Corp. completes Phase 2 clinical study with Topical Interferon Alpha-2B in patients with low-grade squamous intraepithelial lesions
November 14, 2006
Helix BioPharma Corp. announces fiscal 2006 results
October 26, 2006
Helix BioPharma to present L-DOS47 lung cancer research findings at Zurich conference
June 26, 2006
Helix BioPharma announces Q3 2006 financial results
June 7, 2006
Helix retains leading health care communications firm
June 5, 2006
Helix BioPharma announces Q2 2006 financial results
March 14, 2006
Helix receives milestone payment on biochip license
February 10, 2006
Helix BioPharma signs agreement with the National Research Council of Canada
January 31, 2006
Helix BioPharma signs L-DOS47 manufacturing agreement with QSV Biologics
December 19, 2005
Helix BioPharma announces Q1 2006 financial results
December 15, 2005
Helix closes $5.5 million private placement
November 7, 2005
Helix BioPharma Corp. announces fiscal 2005 results
October 31, 2005
DOS47 scientific paper published in the Journal of Experimental Therapeutics and Oncology
October 24, 2005
Helix closes $4 million private placement
October 4, 2005
Helix receives approval to conduct a clinical trial of Topical Interferon Alpha-2b in Sweden
September 12, 2005
Helix announces appointment of new Chief Financial Officer; Announces 3rd quarter fiscal 2005 financial results and provides development update
June 14, 2005
Helix opens additional sites for its Topical Interferon Alpha-2b Phase II clinical study
June 2, 2005
Helix identifies lead product candidate from DOS47 cancer therapeutic program
May 2, 2005